Clinical Efficacy Of Pulakesuo Added To Levodapo Inhibitor In Non-movement Symptoms Of Parkinson's Disease

Objective To investigate the efficacy and safety of pramipexole in the treatment of non-motor symptoms of Parkinson's Disease. Methods The open randomized controlled trial was performed. Pramipexole was added to Levodopa in the treatment of 72 patients with Parkinson's disease for 3-months.Indicators for Unified Parkinson's disease Rating Scale (UPDRSâ… ,â…¡), Pittsburgh Sleep Quality Index (PSQI), Hamilton Depression Rating Scale (HAMD), mini-mental state examination table (MMSE). All the patients in the pre-treatment, treatment for1, 3 months after the above-mentioned assessment scale, and clinical observation; security indicators for adverse drug reactions, as well as vital signs, physical examination, laboratory tests and electrocardiograms.Result After treating for 1 and 3months,the other scores were significantly improved in the add Pizotifen treated group,except the sleep disorders. Compared with the control group, the treatment of patients with depression, anxiety and cognitive function in areas such as improving the difference was significant, treatment group 3 months after the UPDRSâ…¡score compared with the control group the difference was statistically significant. Conclusion Pizotifen for the treatment of non- motor symptoms of Parkinson's disease can improve the PD patients with depression, cognitive function and improve quality of life of patients, but the sleep disorders of poor results.